Frater R. Tricuspid insufficiency. J Thorac Cardiovasc Surg. 2001 Sep. 122(3):427-9. [QxMD MEDLINE Link].
Topilsky Y, Tribouilloy C, Michelena HI, Pislaru S, Mahoney DW, Enriquez-Sarano M. Pathophysiology of tricuspid regurgitation: quantitative Doppler echocardiographic assessment of respiratory dependence. Circulation. 2010 Oct 12. 122(15):1505-13. [QxMD MEDLINE Link].
Khan IA. Ebstein's anomaly of the tricuspid valve with associated mitral valve prolapse. Tex Heart Inst J. 2001. 28(1):72. [QxMD MEDLINE Link].
Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002 Feb. 77(2):139-47. [QxMD MEDLINE Link].
Luo GH, Ma WG, Sun HS, et al. Correction of traumatic tricuspid insufficiency using the double orifice technique. Asian Cardiovasc Thorac Ann. 2005 Sep. 13(3):238-40. [QxMD MEDLINE Link].
Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated with adverse outcome after tricuspid valve replacement. Circulation. 2011 May 10. 123(18):1929-39. [QxMD MEDLINE Link].
Sugimoto T, Okada M, Ozaki N, et al. Long-term evaluation of treatment for functional tricuspid regurgitation with regurgitant volume: characteristic differences based on primary cardiac lesion. J Thorac Cardiovasc Surg. 1999 Mar. 117(3):463-71. [QxMD MEDLINE Link].
[Guideline] Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012 Oct. 33(19):2451-96. [QxMD MEDLINE Link]. [Full Text].
Ha JW, Chung N, Jang Y, Rim SJ. Tricuspid stenosis and regurgitation: Doppler and color flow echocardiography and cardiac catheterization findings. Clin Cardiol. 2000 Jan. 23(1):51-2. [QxMD MEDLINE Link].
Shah PM, Raney AA. Tricuspid valve disease. Curr Probl Cardiol. 2008 Feb. 33(2):47-84. [QxMD MEDLINE Link].
Vlahos AP, Feinstein JA, Schiller NB, Silverman NH. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. J Am Soc Echocardiogr. 2008 Jun. 21(6):711-4. [QxMD MEDLINE Link].
Yang WI, Shim CY, Kang MK, et al. Vena contracta width as a predictor of adverse outcomes in patients with severe isolated tricuspid regurgitation. J Am Soc Echocardiogr. 2011 Sep. 24(9):1013-9. [QxMD MEDLINE Link].
Campelo-Parada F, Perlman G, Philippon F, et al. First-in-man experience of a novel transcatheter repair system for treating severe tricuspid regurgitation. J Am Coll Cardiol. 2015 Dec 8. 66(22):2475-83. [QxMD MEDLINE Link].
Anderson C, Filsoufi F, Farivar RS, Adams DH. Optimal management of severe tricuspid regurgitation in cardiac transplant recipients. J Heart Lung Transplant. 2001 Feb. 20(2):247. [QxMD MEDLINE Link].
DeLeon MA, Gidding SS, Gotteiner N, Backer CL, Mavroudis C. Successful palliation of Ebstein's malformation on the first day of life following fetal diagnosis. Cardiol Young. 2000 Oct. 10(4):384-7. [QxMD MEDLINE Link].
Filsoufi F, Anyanwu AC, Salzberg SP, et al. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg. 2005 Sep. 80(3):845-50. [QxMD MEDLINE Link].
Gatti G, Maffei G, Lusa AM, Pugliese P. Tricuspid valve repair with the Cosgrove-Edwards annuloplasty system: early clinical and echocardiographic results. Ann Thorac Surg. 2001 Sep. 72(3):764-7. [QxMD MEDLINE Link].
Ibrahim M, Tsang VT, Caruana M, et al. Cone reconstruction for Ebstein's anomaly: Patient outcomes, biventricular function, and cardiopulmonary exercise capacity. J Thorac Cardiovasc Surg. 2015 Apr. 149(4):1144-50. [QxMD MEDLINE Link].
Roberts PA, Boudjemline Y, Cheatham JP, et al. Percutaneous tricuspid valve replacement in congenital and acquired heart disease. J Am Coll Cardiol. 2011 Jul 5. 58(2):117-22. [QxMD MEDLINE Link].
[Guideline] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2. 143(5):e35-e71. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2. 143(5):e72-e227. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Vahanian A, Beyersdorf F, Praz F, et al, for the ESC/EACTS Scientific Document Group; ESC National Cardiac Societies. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021 Aug 28. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Nishimura RA, Otto CM, Bonow RO, et al, for the ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 10. 129(23):e521-643. [QxMD MEDLINE Link]. [Full Text].
Takagi H, Hari Y, Kawai N, Ando T, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation. Catheter Cardiovasc Interv. 2019 Apr 1. 93(5):946-53. [QxMD MEDLINE Link].
Go YY, Dulgheru R, Lancellotti P. The conundrum of tricuspid regurgitation grading. Front Cardiovasc Med. 2018. 5:164. [QxMD MEDLINE Link].

Table. Comparison of Recommendations for tricuspid valve disease Intervention

Table. Comparison of Recommendations for tricuspid valve disease Intervention

Recommendation	AHA/ACC (2014)^[23]	ESC/EACTS (2012)^[8]
Tricuspid valve surgery for patients with severe tricuspid regurgitation(TR) or severe tricuspid stenosis (TS) when undergoing left-sided valve surgery	Class I	Class I
Tricuspid valve surgery for patients with isolated, symptomatic severe TS.	Class I	Class I
Tricuspid valve surgery for patients with isolated, symptomatic severe TR without severe right ventricle dysfunction		Class I
Tricuspid valve repair for patients with mild, moderate, or greater functional TR (stage B) at the time of left-sided valve surgery with either 1) tricuspid annular dilation or 2) prior evidence of right HF	Class IIa-Reasonable	Class IIa-Reasonable
Tricuspid valve surgery for patients with symptoms due to severe primary TR that are unresponsive to medical therapy (stage D).	Class IIa-Reasonable
After left-sided valve surgery, surgery for patients with severe TR who are symptomatic or have progressive right ventricular dilatation/dysfunction, in the absence of left-sided valve dysfunction, severe right or left ventricular dysfunction, and severe pulmonary vascular disease		Class IIa-Reasonable
Tricuspid valve repair for patients with moderate functional TR (stage B) and pulmonary artery hypertension at the time of left-sided valve surgery	Class IIb-Consider
Tricuspid valve surgery for asymptomatic or minimally symptomatic patients with severe primary TR (stage C) and progressive degrees of moderate or greater RV dilation and/or systolic dysfunction.	Class IIb-Consider	Class IIa-Reasonable
Reoperation for isolated tricuspid valve repair or replacement for persistent symptoms due to severe TR (stage D) in patients who have undergone previous left-sided valve surgery and who do not have severe pulmonary hypertension or significant RV systolic dysfunction.	Class IIb-Consider
Percutaneous balloon tricuspid commissurotomy in patients with isolated, symptomatic severe TS without accompanying TR.	Class IIb-Consider

Back to List

Author

Mary C Mancini, MD, PhD, MMM

Mary C Mancini, MD, PhD, MMM is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Terrence X O'Brien, MD, MS, FACC Professor of Medicine/Cardiology, Director, Clinical Cardiovascular Research, Medical University of South Carolina College of Medicine; Director, Echocardiography Laboratory, Veterans Affairs Medical Center of Charleston

Terrence X O'Brien, MD, MS, FACC is a member of the following medical societies: American College of Cardiology, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, South Carolina Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Martin Gerard Keane, MD, FACC, FAHA Associate Professor, Cardiovascular Medicine Division, Department of Medicine, University of Pennsylvania School of Medicine

Martin Gerard Keane, MD, FACC, FAHA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Heart Association, American Society of Echocardiography, Pennsylvania Medical Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Ronald J Oudiz, MD, FACP, FACC, FCCP Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society

Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Ikaria Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; Lung LLC Clinical Trials + honoraria; Bayer Grant/research funds Consulting; Medtronic Consulting fee Consulting; Novartis Consulting fee Consulting

Frank M Sheridan, MD Cardiologist, Providence Everett Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment